Drug profile · INN
ketoprofen
DIRACTIN
ketoprofen (DIRACTIN) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — ketoprofen
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 0
- Data quality
- 0.89
Quick answer
ketoprofen (DIRACTIN) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Related & competitor drugs
Related patents
-
CA 3079530
COMPOSITION LIQUIDE STABLE DE KETOPROFENE, SELS ET ENANTIOMERES DE CELUI-CI
granted -
EP 1613300
PHOTOSTABILISIERTE TOPISCHE FORMULIERUNGEN VON KETOPROFEN MIT ZWEI UV-FILTERN
expired -
EP 1526849
TOPISCHE ZUSAMMENSETZUNG ENTHALTEND KETOPROFEN STABILISIERT MIT SULISOBENZON
expired -
EP 1488787
Topisch anzuwendende stabilisierte Arzneimittel enthaltend Ketoprofen
expired
Frequently asked questions
What is ketoprofen?
ketoprofen (DIRACTIN) is a cyclooxygenase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ketoprofen?
DIRACTIN is a marketed brand name for ketoprofen. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ketoprofen?
ketoprofen has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.